Abstract
ObjectivesTo compare the diagnostic value of the SARC-F, MRSA-7 and MRSA-5 questionnaires in screening for sarcopenia in inpatients with chronic heart failure (CHF).PatientsA total of 355 CHF patients hospitalized from January 2019 to August 2019 who met the study’s selection criteria were included in the analysis.MeasurementsHandgrip strength and gait speed were measured, and bioelectrical impedance analysis (BIA) was used to estimate appendicular skeletal muscle mass. The sensitivity/specificity of the SARC-F, MRSA-7 and MRSA-5 questionnaires was evaluated.ResultsThe diagnostic criteria of the Asia Working Group for Sarcopenia (AWGS) were used as the gold standard for diagnosing sarcopenia. The prevalence of sarcopenia was 55.8% according to the AWGS diagnostic criteria, 31.0% according to the SARC-F, 73.0% according to the MRSA-7, and 71.3% according to the MRSA-5. Using the AWGS criteria as the gold standard, the SARC-F had a sensitivity of 52.5% and a specificity of 96.2% in the whole study population, the MRSA-7 had a sensitivity of 92.4% and a specificity of 51.6%, and the MRSA-5 had a sensitivity of 93.9% and a specificity of 57.3%. The areas under the ROC curves for the SARC-F, MRSA-7 and MRSA-5 were 0.78, 0.74 and 0.77, respectively.ConclusionsThe MSRA-7 and MSRA-5 may serve as novel screening tools for sarcopenia in hospitalized patients with CHF. The SARC-F, a classic screening tool, is also suitable for this population. The MSRA-7 and MSRA-5 have better sensitivity, whereas the SARC-F has better specificity.
Highlights
Heart failure (HF) is a common chronic disease that is the terminal stage of all kinds of heart disease, and the incidence and prevalence of HF are increasing year by year
The prevalence of sarcopenia was 55.8% according to the Asia Working Group for Sarcopenia (AWGS) diagnostic criteria, 31.0% according to the SARC-F, 73.0% according to the MRSA-7, and 71.3% according to the MRSA-5
In the entire population, compared with the gold standard of the AWGS, the SARC-F had a sensitivity of 52.5% and a specificity of 96.2%; the MSRA-7 had a sensitivity of 92.4% and a specificity of 51.6%; and the MSRA-5 had a sensitivity of 93.9% and a specificity of 57.3% (Table 2)
Summary
Heart failure (HF) is a common chronic disease that is the terminal stage of all kinds of heart disease, and the incidence and prevalence of HF are increasing year by year. When HF occurs, myocardial contractility decreases, peripheral skeletal muscle blood perfusion is insufficient, and skeletal muscle mass and muscle function decline, leading to sarcopenia. Sarcopenia is a syndrome associated with ageing characterized by a progressive and overall loss of skeletal muscle and strength, which may lead to disability, reduced quality of life and even death. Patients with HF combined with sarcopenia often have weakened muscle strength and decreased exercise ability and are prone to develop weakness and cardiogenic cachexia, increasing the rate of rehospitalization and mortality [2, 3]. Research on sarcopenia in China started late, and research on chronic
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
